Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Dyadic International, Inc.NASDAQ: DYAI

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $112.08K rose 587.1% year over year, ahead of the -7474.5% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +163.0% a year.

Context

  • Accounts receivables amounted to 69.6% of revenue in FY2025, up 63.7 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +587.1% holds above the trailing-twelve-month pace of -7474.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$112.08K+164.2% QoQ
Last fiscal yearDec 2025
-$857.85K-517.9% YoY
LTMMar 2026
-$762.08K-7474.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+587.1%——
1 year-517.9%——
3-year CAGR+163.0%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(857.85K) USD
Year-over-year change
-517.9%

Accounts Receivables vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7474.5% is the lowest of 6, against a peer median of -45.4%.
  • Accounts receivables amounts to 25.6% of revenue for DYAI, versus a peer median of 2.6%.
DYAI Competitors
Accounts Receivables for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$7.55M USD+290.3%—28.4%
DYAIDyadic International, Inc.LTM Mar 2026$762.08K USD-7474.5%+163.0%25.6%
ATHEAlterity Therapeutics LimitedFY2025A$104.07K AUD-97.7%—1.9%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$80.41K USD-45.4%——
RNXTRenovoRx, Inc.LTM Mar 2026$38K USD-80.9%—2.6%
PYPDPolyPid Ltd.LTM Dec 2025$0 USD———
VERUVeru Inc.LTM Mar 2026$0 USD+100.0%——
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding DYAI) —-45.4%—2.6%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Depreciation & Amortization0000(24.17K)
Deferred Income Tax00000
Stock-Based Compensation1.78M1.89M1.24M1.13M930.18K
Change in Working Capital1.19M(321.17K)(143.21K)754.53K660.8K
Accounts Receivables(13.92K)(47.18K)(93.13K)205.26K(857.85K)
Inventory00000
Accounts Payables549.56K(248.13K)(651.17K)(180.18K)314.45K
Other Working Capital652.59K(25.87K)601.09K729.45K1.2M
Other Non-Cash Items(1.18M)83.71K(1.03M)(46.45K)95.6K
Operating Cash Flow(11.28M)(8.08M)(6.73M)(3.97M)(5.7M)
Capital Expenditures000(4)0
Acquisitions (Net)00000
Purchases of Investments(11.28M)(9.87M)(3M)(7.34M)(5.95M)
Sales of Investments16.51M7.5M10.45M5.47M6.03M
Other Investing Activities00000
Investing Cash Flow5.22M(2.37M)7.45M(1.88M)82.09K
Debt Repayment0005.82M0
Common Stock Issued00024.25K4.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.23M543.59K000
Financing Cash Flow1.23M543.59K05.85M4.96M
Effect of Forex Changes(63.26K)(44.74K)(2.39K)(5.8K)1.94K
Net Change in Cash(4.89M)(9.95M)720.76K(8.28K)(653.25K)
Free Cash Flow(11.28M)(8.08M)(6.73M)(3.97M)(5.7M)

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.